A.R.T. Advisors’s Nektar Therapeutics NKTR Stock Holding History

A.R.T. Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-2,673	Closed	-$730K	–	1594
2019 Q3	$730K	Buy	+2,673	New	+$980K	0.04%	699
2019 Q2	–	Sell	-447	Closed	-$225K	–	1538
2019 Q1	$225K	Sell	447 -4,514	-91%	-$2.68M	0.01%	1048
2018 Q4	$2.45M	Buy	4,961 +3,405	+219%	+$2.06M	0.16%	179
2018 Q3	$1.42M	Sell	1,556 -11,434	-88%	-$9.76M	0.06%	423
2018 Q2	$9.51M	Buy	+12,990	New	+$15M	0.39%	31
2017 Q1	–	Sell	-1,500	Closed	-$276K	–	1615
2016 Q4	$276K	Buy	+1,500	New	+$305K	0.02%	967
2016 Q2	–	Sell	-1,758	Closed	-$362K	–	1543
2016 Q1	$362K	Buy	+1,758	New	+$338K	0.02%	978
2014 Q2	–	Sell	-7,048	Closed	-$1.28M	–	1453
2014 Q1	$1.28M	Sell	7,048 -7,907	-53%	-$1.56M	0.07%	405
2013 Q4	$2.55M	Buy	+14,955	New	+$2.41M	0.14%	211

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

A.R.T. Advisors's NKTR Position: Q4 2019 in Review

A.R.T. Advisors sold out of Nektar Therapeutics (NKTR) in Q4 2019, closing a stake of 2,673 shares — an estimated $730K sold.

A.R.T. Advisors first reported a position in NKTR in Q4 2013 and held it in 9 quarters. The position peaked at $9.51M in Q2 2018. 280 funds tracked by Wall St. Rank hold NKTR as of Q4 2019.

A.R.T. Advisors reported no remaining Nektar Therapeutics position as of Q4 2019 after selling out during the quarter.
A.R.T. Advisors sold 2,673 Nektar Therapeutics shares in Q4 2019, an estimated $730K.
A.R.T. Advisors first reported a position in Nektar Therapeutics in Q4 2013 and held it in 9 quarters.
A.R.T. Advisors's Nektar Therapeutics position peaked at $9.51M in Q2 2018.
280 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2019.

Based on A.R.T. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.